

# Naomi Kiyota

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1447388/publications.pdf>

Version: 2024-02-01

185  
papers

10,858  
citations

116194

36  
h-index

37326

100  
g-index

195  
all docs

195  
docs citations

195  
times ranked

14094  
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module (EORTC QLQ-HN43) exemplified by the Swallowing scale. <i>Quality of Life Research</i> , 2022, 31, 841-853.	1.5	3
2	Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF-CRT) for locally advanced squamous cell carcinoma of the external auditory canal. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 2805-2810.	0.8	3
3	Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody. <i>International Journal of Hematology</i> , 2022, 115, 7-10.	0.7	9
4	Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. <i>Oncologist</i> , 2022, 27, e194-e198.	1.9	18
5	Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial. <i>International Journal of Hematology</i> , 2022, , 1.	0.7	4
6	Systemic therapy for salivary gland malignancy: current status and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 293-302.	0.6	12
7	A phase I study of LCL161, a novel oral pan- $\epsilon$ -inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	3
8	Management of elderly patients with head and neck cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 313-321.	0.6	3
9	Identification of Breast Cancer Stem Cells Using a Newly Developed Long-acting Fluorescence Probe, C5S-A, Targeting ALDH1A1. <i>Anticancer Research</i> , 2022, 42, 1199-1205.	0.5	4
10	Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1980-1990.	0.8	74
11	Impact of baseline tumor burden on overall survival in patients with radioiodine- $\epsilon$ -refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. <i>Cancer</i> , 2022, 128, 2281-2287.	2.0	8
12	Safety and immunogenicity of the COVID-19 vaccine BNT162b2 in patients undergoing chemotherapy for solid cancer. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 516-520.	0.8	17
13	Human papillomavirus-related oropharyngeal carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 700-706.	0.6	1
14	Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge. <i>Molecular and Clinical Oncology</i> , 2022, 16, 104.	0.4	3
15	Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib. <i>Dermatology Reports</i> , 2022, 14, .	0.4	2
16	Promising Efficacy of a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients Treated with Anti-CD20 Antibody Who Failed 2-Dose Vaccination. <i>Vaccines</i> , 2022, 10, 965.	2.1	5
17	Multi-institutional Survey of Squamous Cell Carcinoma of the External Auditory Canal in Japan. <i>Laryngoscope</i> , 2021, 131, E870-E874.	1.1	15
18	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	1.8	49

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 65-71.	1.1	3
20	Device-related & Mycobacterium mageritense & Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer. <i>Internal Medicine</i> , 2021, 60, 3485-3488.	0.3	7
21	Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cells. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1093.	0.3	5
22	Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma. <i>Radiation Oncology</i> , 2021, 16, 1.	1.2	74
23	Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 14, 68.	0.4	4
24	New proposal to revise the classification for squamous cell carcinoma of the external auditory canal and middle ear. <i>Journal of Laryngology and Otology</i> , 2021, 135, 297-303.	0.4	11
25	Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. <i>European Journal of Cancer</i> , 2021, 147, 51-57.	1.3	26
26	Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib. <i>Thyroid</i> , 2021, 31, 1226-1234.	2.4	24
27	Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients. <i>International Journal of Hematology</i> , 2021, 114, 319-324.	0.7	2
28	Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1619-1627.	1.0	6
29	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	1.7	17
30	Sites of invasion of cancer of the external auditory canal predicting oncologic outcomes. <i>Head and Neck</i> , 2021, 43, 3097-3105.	0.9	7
31	Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638123.	1.3	3
32	Did the Randomized Phase III KEYNOTE-181 Study of Pembrolizumab for Esophageal Cancer Yield Negative or Positive Results?. <i>Journal of Clinical Oncology</i> , 2021, 39, 2317-2318.	0.8	2
33	LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651. <i>Annals of Oncology</i> , 2021, 32, S1310-S1311.	0.6	25
34	Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial. <i>Medical Oncology</i> , 2021, 38, 128.	1.2	11
35	Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events. <i>Anticancer Research</i> , 2021, 41, 1021-1026.	0.5	11
36	Microsatellite instability-high colorectal cancer patient-derived xenograft models for cancer immunity research. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1358.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2021, 51, 173-179.	0.6	15
38	Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies. Cancer Science, 2021, 112, 725-733.	1.7	3
39	Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base. Laryngoscope Investigative Otolaryngology, 2021, 6, 1347-1352.	0.6	2
40	Blowing time ratio and high-resolution manometry to evaluate swallowing function of patients with oral and oropharyngeal cancer. Auris Nasus Larynx, 2021, , .	0.5	0
41	Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody. Blood, 2021, 138, 534-534.	0.6	2
42	Pan-Asian adaptation of the EHNSESMOESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open, 2021, 6, 100309.	2.0	29
43	Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan. Advances in Therapy, 2020, 37, 3850-3862.	1.3	23
44	Immunotherapy for squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2020, 50, 1089-1096.	0.6	39
45	Quality of Life in Patients With Hypoparathyroidism After Treatment for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4652-e4660.	1.8	33
46	Results from a 1-day workshop on the assessment of quality of life in cancer patients: a joint initiative of the Japan Clinical Oncology Group and the European Organisation for Research and Treatment of Cancer. Japanese Journal of Clinical Oncology, 2020, 50, 1333-1341.	0.6	1
47	Ibuprofen gargle for chemo- or Chemoradiotherapy-induced Oral Mucositis: a feasibility study. Journal of Pharmaceutical Health Care and Sciences, 2020, 6, 12.	0.4	7
48	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head and Neck, 2020, 42, 2852-2862.	0.9	26
49	Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer. International Journal of Clinical Oncology, 2020, 25, 1270-1277.	1.0	12
50	Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).. Journal of Clinical Oncology, 2020, 38, 6502-6502.	0.8	47
51	Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report. Molecular and Clinical Oncology, 2020, 14, 1-1.	0.4	6
52	Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report. Molecular and Clinical Oncology, 2020, 14, 30.	0.4	1
53	Control of Lung Metastases and Colon Polyposis with Lenvatinib Therapy in a Patient with Cribriform-Morular Variant of Papillary Thyroid Carcinoma and an APC Gene Mutation: A Case Study. Thyroid, 2019, 29, 1511-1517.	2.4	9
54	Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncology, 2019, 96, 7-14.	0.8	45

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Nivolumab for Non-Cutaneous Melanoma: A Retrospective Analysis from a Single Institution. <i>Annals of Oncology</i> , 2019, 30, vi91.	0.6	1
56	Scheduled cessation in treatment using lenvatinib for differentiated thyroid carcinoma. <i>Annals of Oncology</i> , 2019, 30, vi124.	0.6	0
57	Post-marketing survey of safety and efficacy of nivolumab for recurrent or metastatic head and neck cancer in Japan. <i>Annals of Oncology</i> , 2019, 30, vi82.	0.6	0
58	Nutritional support dependence after curative chemoradiotherapy in head and neck cancer: supplementary analysis of a phase II trial (JCOG0706S1). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 1009-1015.	0.6	1
59	Controversies in relation to neck management in NO early oral tongue cancer. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 297-305.	0.6	32
60	A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 589-595.	0.6	19
61	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2019, 5, 1170.	3.4	34
62	Pharmacokinetic study of the oral fluorouracil antitumor agent Sâ€ in patients with impaired renal function. <i>Cancer Science</i> , 2019, 110, 1987-1994.	1.7	6
63	Exploratory analysis of prognostic factors for lenvatinib in radioiodineâ€refractory differentiated thyroid cancer. <i>Head and Neck</i> , 2019, 41, 3023-3032.	0.9	35
64	Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE). <i>Oncologist</i> , 2019, 24, 885-e413.	1.9	10
65	A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEX) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study). <i>Frontiers in Oncology</i> , 2019, 9, 6.	1.3	9
66	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 86.	1.3	71
67	Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin. <i>Oncogene</i> , 2019, 38, 767-779.	2.6	86
68	Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2010-2015.	0.5	1
69	A Phase II study of the safety and efficacy ofÂlenvatinib in patients with advanced thyroidÂcancer. <i>Future Oncology</i> , 2019, 15, 717-726.	1.1	104
70	Impact of retropharyngeal lymph node dissection in the surgical treatment of hypopharyngeal cancer. <i>Head and Neck</i> , 2019, 41, 1738-1744.	0.9	6
71	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQâ€HN43: Phase IV. <i>Head and Neck</i> , 2019, 41, 1725-1737.	0.9	69
72	Clinical impact of cachexia in unresectable locally advanced head and neck cancer: supplementary analysis of a phase II trial (JCOG0706-S2). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 37-41.	0.6	14

#	ARTICLE	IF	CITATIONS
73	Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).. Journal of Clinical Oncology, 2019, 37, 6081-6081.	0.8	6
74	Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.. Journal of Clinical Oncology, 2019, 37, 68-68.	0.8	0
75	Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma. Cancer Research, 2019, 79, CT137-CT137.	0.4	10
76	Abstract CT137: Phase II study of trastuzumab and docetaxel therapy in patients with HER2-positive recurrent and/or metastatic salivary gland carcinoma. , 2019, , .		0
77	Treatmentâ€emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer, 2018, 124, 2365-2372.	2.0	77
78	Nivolumab vs investigatorâ€™s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncology, 2018, 81, 45-51.	0.8	589
79	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Annals of Oncology, 2018, 29, 1004-1009.	0.6	68
80	Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. Oral Oncology, 2018, 76, 52-60.	0.8	29
81	Expression of programmed deathâ€1 in sentinel lymph nodes of breast cancer. Journal of Surgical Oncology, 2018, 117, 1131-1136.	0.8	3
82	Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies. Annals of Oncology, 2018, 29, vii61.	0.6	2
83	Three-weekly cisplatin or weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinomaâ€”the jury is still out. Therapeutic Radiology and Oncology, 2018, 2, 39-39.	0.2	0
84	Efficacy and safety of nivolumab for previously treated non-squamous cell carcinoma of the head and neck. Annals of Oncology, 2018, 29, vii66.	0.6	1
85	Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma. Case Reports in Oncology, 2018, 11, 735-741.	0.3	12
86	Randomized phase III study to evaluate the value of omission of prophylactic neck dissection for stage I/II tongue cancer: Japan Clinical Oncology Group study (JCOG1601, RESPOND). Japanese Journal of Clinical Oncology, 2018, 48, 1105-1108.	0.6	13
87	Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria. Auris Nasus Larynx, 2018, 45, 1249-1252.	0.5	9
88	CheckMate 141: 1â€Year Update and Subgroup Analysis of Nivolumab as Firstâ€Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist, 2018, 23, 1079-1082.	1.9	70
89	Role of intensive nutrition support and prophylactic percutaneous endoscopic gastrostomy during concomitant chemoradiotherapy for oropharyngeal cancer. International Journal of Clinical Oncology, 2018, 23, 1023-1028.	1.0	5
90	Nivolumab (nivo) vs investigatorâ€™s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.. Journal of Clinical Oncology, 2018, 36, 6028-6028.	0.8	9

#	ARTICLE	IF	CITATIONS
91	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <i>Oncotarget</i> , 2018, 9, 18540-18547.	0.8	15
92	3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture. <i>Anticancer Research</i> , 2018, 38, 2831-2839.	0.5	9
93	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. <i>Journal of Japanese Society of Oral Oncology</i> , 2018, 30, 144-150.	0.0	0
94	Immune check point inhibitors for head and neck cancer. <i>Japanese Journal of Head and Neck Cancer</i> , 2018, 44, 336-341.	0.0	0
95	Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: A randomized left-right comparative evaluation (APPEARANCE).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10093-10093.	0.8	0
96	Abstract 653: A comparative analysis of pathological features and molecular genetics between salivary duct carcinoma and adenocarcinoma, not otherwise specified. , 2018, , .		0
97	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. <i>Cancer Research</i> , 2018, 78, CT116-CT116.	0.4	4
98	Modified TALK Score for Japanese Patients with Laryngeal and Hypopharyngeal Cancers to Predict the Possibility of Laryngeal Preservation by Concurrent Chemoradiotherapy. <i>Kobe Journal of Medical Sciences</i> , 2018, 63, E113-E122.	0.2	0
99	The EORTC module for quality of life in patients with thyroid cancer: phase III. <i>Endocrine-Related Cancer</i> , 2017, 24, 197-207.	1.6	34
100	Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. <i>European Journal of Cancer</i> , 2017, 75, 213-221.	1.3	59
101	Quality of life and cost-utility of surgical treatment for patients with spinal metastases: prospective cohort study. <i>International Orthopaedics</i> , 2017, 41, 1265-1271.	0.9	24
102	Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo. <i>European Journal of Dermatology</i> , 2017, 27, 177-178.	0.3	1
103	Japanese Clinical Practice Guideline for Head and Neck Cancer. <i>Auris Nasus Larynx</i> , 2017, 44, 375-380.	0.5	44
104	Prospective Cohort Study of Performance Status and Activities of Daily Living After Surgery for Spinal Metastasis. <i>Clinical Spine Surgery</i> , 2017, 30, E1026-E1032.	0.7	20
105	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. <i>Oral Oncology</i> , 2017, 73, 138-146.	0.8	90
106	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	5.1	325
107	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017, 22, 1056-1066.	1.9	122
108	Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. <i>Thyroid</i> , 2017, 27, 1135-1141.	2.4	37

#	ARTICLE	IF	CITATIONS
109	Lenvatinib for Anaplastic Thyroid Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 25.	1.3	141
110	Prognostic value of ALDH2 polymorphism for patients with oropharyngeal cancer in a Japanese population. <i>PLoS ONE</i> , 2017, 12, e0187992.	1.1	10
111	Optimal use of lenvatinib in the treatment of advanced thyroid cancer. <i>Cancers of the Head &amp; Neck</i> , 2017, 2, 7.	6.2	23
112	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	0.8	20
113	[18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcomes for oropharyngeal and hypopharyngeal cancer treated with definitive radiotherapy. <i>Nagoya Journal of Medical Science</i> , 2017, 79, 27-36.	0.6	3
114	A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 91-99.	1.1	49
115	Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. <i>Head and Neck</i> , 2016, 38, E949-53.	0.9	45
116	Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. <i>Auris Nasus Larynx</i> , 2016, 43, 677-684.	0.5	37
117	A prospective study on the efficacy of two-dose influenza vaccinations in cancer patients receiving chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 448-452.	0.6	18
118	The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 1165-1170.	1.1	13
119	Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study. <i>Thyroid</i> , 2016, 26, 1605-1613.	2.4	41
120	Multicenter Phase 2 Study of Cisplatin and 5-Fluorouracil With Concurrent Radiation Therapy as an Organ Preservation Approach in Patients With Squamous Cell Carcinoma of the Cervical Esophagus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 976-984.	0.4	45
121	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016, 375, 1856-1867.	13.9	3,845
122	Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 281-288.	1.1	23
123	FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT. <i>European Radiology</i> , 2016, 26, 1018-1030.	2.3	33
124	Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6009-6009.	0.8	32
125	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6026-6026.	0.8	9
126	Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6088-6088.	0.8	22



#	ARTICLE	IF	CITATIONS
127	First-line chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma with or without cetuximab: a single institution experience. Japanese Journal of Head and Neck Cancer, 2016, 42, 432-437.	0.0	1
128	Treatment outcome of 72 patients with parotid cancer. Japanese Journal of Head and Neck Cancer, 2016, 42, 51-56.	0.0	5
129	Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-resistant differentiated thyroid cancer. Cancer Science, 2015, 106, 1714-1721.	1.7	111
130	Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. Head and Neck, 2015, 37, 1358-1367.	0.9	65
131	Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study. Case Reports in Oncology, 2015, 8, 323-331.	0.3	0
132	Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncology Reports, 2015, 33, 1837-1843.	1.2	621
133	Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 2015, 372, 621-630.	13.9	1,526
134	Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2015, 16, 583-594.	5.1	358
135	Adjuvant treatment for post-operative head and neck squamous cell carcinoma. Japanese Journal of Clinical Oncology, 2015, 45, 2-6.	0.6	25
136	Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Science, 2015, 106, 726-733.	1.7	17
137	Effect of age and lenvatinib treatment on overall survival for patients with I-refractory differentiated thyroid cancer in SELECT.. Journal of Clinical Oncology, 2015, 33, 6048-6048.	0.8	8
138	Early tumor shrinkage (ETS) and deepness of response (DpR) in patients with metastatic esophageal cancer receiving a first-line treatment with DCF: Exploratory analysis of the JCOG0807.. Journal of Clinical Oncology, 2015, 33, 183-183.	0.8	0
139	Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients. PLoS ONE, 2014, 9, e104215.	1.1	9
140	Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e113259.	1.1	40
141	Regulation of MET Kinase Inhibitor Resistance by Copy Number of MET in Gastric Carcinoma Cells. Oncology Research, 2014, 21, 287-293.	0.6	2
142	Randomized Phase II/III Trial of Post-operative Chemoradiotherapy Comparing 3-Weekly Cisplatin with Weekly Cisplatin in High-risk Patients with Squamous Cell Carcinoma of Head and Neck: Japan Clinical Oncology Group Study (JCOG1008). Japanese Journal of Clinical Oncology, 2014, 44, 770-774.	0.6	56
143	A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric Cancer, 2014, 17, 161-172.	2.7	18
144	Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. Clinical Journal of Gastroenterology, 2014, 7, 255-259.	0.4	16

#	ARTICLE	IF	CITATIONS
145	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup> I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2014, 32, LBA6008-LBA6008.	0.8	7
146	A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with <sup>131</sup> I-refractory differentiated thyroid cancer (SELECT).. Journal of Clinical Oncology, 2014, 32, LBA6008-LBA6008.	0.8	23
147	Prognostic Value of FDG PET Imaging in Patients with Laryngeal Cancer. PLoS ONE, 2014, 9, e96999.	1.1	27
148	Safety profile and efficacy of Chemotherapy with Docetaxel and Cisplatin (DC) for Recurrent or Metastatic Head and Neck Cancer – A Retrospective Analysis in a Single Institution. Japanese Journal of Head and Neck Cancer, 2014, 40, 490-496.	0.0	2
149	Therapeutic strategy for advanced laryngeal and hypopharyngeal cancer. Japanese Journal of Head and Neck Cancer, 2014, 40, 406-411.	0.0	3
150	Role of the medical oncologist in multi-disciplinary treatment for head and neck cancer. Japanese Journal of Head and Neck Cancer, 2014, 40, 294-296.	0.0	0
151	Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.. Journal of Clinical Oncology, 2014, 32, 2579-2579.	0.8	1
152	TYRO3 as a potential therapeutic target in breast cancer. Anticancer Research, 2014, 34, 3337-45.	0.5	21
153	A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2013, 71, 991-998.	1.1	6
154	Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Investigational New Drugs, 2013, 31, 293-303.	1.2	16
155	Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investigational New Drugs, 2013, 31, 1158-1168.	1.2	22
156	Prediction of Glomerular Filtration Rate in Cancer Patients by an Equation for Japanese Estimated Glomerular Filtration Rate. Japanese Journal of Clinical Oncology, 2013, 43, 271-277.	0.6	19
157	Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncology Reports, 2013, 30, 1802-1806.	1.2	6
158	Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 4074-4074.	0.8	1
159	Two cases of melanoma to cervical lymph nodes from an unknown primary site. Japanese Journal of Head and Neck Cancer, 2013, 39, 72-76.	0.0	0
160	Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.. , 2013, , .		0
161	Radiotherapy for Stage I or II hypopharyngeal carcinoma. Journal of Radiation Research, 2012, 53, 892-899.	0.8	11
162	Phase II Feasibility Trial of Adjuvant Chemoradiotherapy with 3-weekly Cisplatin for Japanese Patients with Post-operative High-risk Squamous Cell Carcinoma of the Head and Neck. Japanese Journal of Clinical Oncology, 2012, 42, 927-933.	0.6	57

#	ARTICLE	IF	CITATIONS
163	Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 1950-1957.	1.2	37
164	Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification. <i>International Journal of Oncology</i> , 2012, 41, 551-558.	1.4	26
165	Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. <i>Investigational New Drugs</i> , 2012, 30, 1055-1064.	1.2	56
166	Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. <i>Investigational New Drugs</i> , 2012, 30, 1352-1360.	1.2	100
167	Understanding the characteristics of molecular targeting agents for proper usage. <i>Japanese Journal of Head and Neck Cancer</i> , 2012, 38, 399-402.	0.0	2
168	A safety profile of sequential therapy for unresectable head and neck cancer: A retrospective analysis in a single institution. <i>Japanese Journal of Head and Neck Cancer</i> , 2012, 38, 374-379.	0.0	0
169	Phase II trial of chemoradiotherapy concurrent withÂS-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5542-5542.	0.8	1
170	Daily performance status-based target physical activity of early rehabilitation for hematologic malignancy patients after allogeneic hematopoietic stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2012, 30, e17020-e17020.	0.8	0
171	Successful neutrophil engraftment by reduced use of granulocyte colony-stimulating factor after allogeneic hematopoietic stem cell transplantation with mycophenolate mofetil for graft-versus-host disease prophylaxis. <i>International Journal of Hematology</i> , 2011, 93, 765-770.	0.7	1
172	Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer. <i>Annals of Oncology</i> , 2011, 22, 175-180.	0.6	13
173	Post-operative radiation therapy for locally advanced hypopharyngeal carcinoma. <i>Japanese Journal of Head and Neck Cancer</i> , 2011, 37, 62-66.	0.0	0
174	Approaches to encourage broad use of adjuvant chemoradiotherapy for postoperative high-risk patients with squamous cell carcinoma of the head and neck in Japan. <i>Japanese Journal of Head and Neck Cancer</i> , 2011, 37, 362-365.	0.0	0
175	Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma. <i>Rare Tumors</i> , 2010, 2, 151-153.	0.3	14
176	Future perspectives in head and neck oncology in Japan -Current status and challenges facing clinical trials for head and neck oncology in Japan-. <i>Japanese Journal of Head and Neck Cancer</i> , 2010, 36, 278-281.	0.0	0
177	Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 225-230.	0.6	9
178	Phase II Trial of Concurrent Chemoradiotherapy with S-1 Plus Cisplatin in Patients with Unresectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Japan Clinical Oncology Group Study (JCOG0706). <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 460-463.	0.6	15
179	Effectiveness of prophylactic percutaneous endoscopic gastrostomy for oropharyngeal cancer patients undergoing concurrent chemoradiotherapy. <i>Japanese Journal of Head and Neck Cancer</i> , 2009, 35, 287-292.	0.0	6
180	Nonplatinumâ€based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma. <i>Cancer</i> , 2008, 112, 885-891.	2.0	35

#	ARTICLE	IF	CITATIONS
181	Rabeprazole-based eradication therapy for <i>Helicobacter pylori</i> : a large-scale study in Japan. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1105-1113.	1.9	51
182	Influence of cure of <i>Helicobacter pylori</i> infection on gastric acidity and gastroesophageal reflux: study by 24-h pH monitoring in patients with gastric or duodenal ulcer. <i>Journal of Gastroenterology</i> , 2005, 40, 350-360.	2.3	17
183	New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?. <i>Therapeutic Radiology and Oncology</i> , 0, 4, 5-5.	0.2	1
184	Severe and delayed-onset acneiform eruptions as an adverse reaction to regorafenib. <i>Dermatology Reports</i> , 0, , .	0.4	0
185	Reply to V. Noronha et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0